T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Arteris
AIP
$1.14B
| $21.5M | ﹤0.01% |
443,481
+421,967
| +1,961% | +$13.5M |
|
1127
Best Buy
BBY
$18.9B
| $21.5M | ﹤0.01% |
283,702
+136
| +0% | +$9.03K |
|
|
CAI
1128
Caris Life Sciences
CAI
$8.97B
| $21.5M | ﹤0.01% |
1,205,390
-3,166,381
| -72% | -$56.7M |
|
1129
Healthpeak Properties
DOC
$13.9B
| $21.5M | ﹤0.01% |
1,003,467
-2,257
| -0.2% | -$42.1K |
|
1130
Celsius Holdings
CELH
$7.08B
| $21.3M | ﹤0.01% |
727,341
-123,265
| -14% | -$3.89M |
|
1131
Portland General Electric
POR
$5.2B
| $21.3M | ﹤0.01% |
410,316
+116,094
| +39% | +$5.89M |
|
1132
Associated Banc-Corp
ASB
$5.47B
| $21.1M | ﹤0.01% |
684,608
+243,430
| +55% | +$6.86M |
|
1133
Jacobs Solutions
J
$16.2B
| $21.1M | ﹤0.01% |
167,112
+467
| +0.3% | +$57.4K |
|
|
SION
1134
Sionna Therapeutics
SION
$231M
| $21M | ﹤0.01% |
478,016
-278,360
| -37% | -$11.1M |
|
1135
CACI
CACI
$13.6B
| $20.9M | ﹤0.01% |
45,089
-13,089
| -22% | -$6.68M |
|
1136
Pulse Biosciences
PLSE
$3.73B
| $20.8M | ﹤0.01% |
748,638
+733,779
| +4,938% | +$17.3M |
|
1137
LyondellBasell Industries
LYB
$18.8B
| $20.7M | ﹤0.01% |
393,592
-934,946
| -70% | -$64.5M |
|
1138
Atour Lifestyle Holdings
ATAT
$4.46B
| $20.7M | ﹤0.01% |
651,527
-115,932
| -15% | -$4.15M |
|
|
PBLS
1139
Parabilis Medicines Inc
PBLS
$4.02B
| $20.6M | ﹤0.01% |
+751,947
| New | +$20.8M |
|
1140
Build-A-Bear
BBW
$312M
| $20.5M | ﹤0.01% |
669,597
+280,528
| +72% | +$10.1M |
|
1141
SL Green Realty
SLG
$3.49B
| $20.4M | ﹤0.01% |
394,953
-8,320
| -2% | -$371K |
|
1142
Autoliv
ALV
$8.35B
| $20.4M | ﹤0.01% |
175,342
+31,020
| +21% | +$3.69M |
|
1143
Oshkosh
OSK
$8.2B
| $20.3M | ﹤0.01% |
132,530
+20,471
| +18% | +$2.88M |
|
1144
MoonLake Immunotherapeutics
MLTX
$984M
| $20.3M | ﹤0.01% |
1,041,527
-253,334
| -20% | -$4.59M |
|
1145
Rithm Capital
RITM
$5.07B
| $20.1M | ﹤0.01% |
2,144,328
+498,002
| +30% | +$4.75M |
|
1146
Unifirst Corp
UNF
$4.69B
| $20M | ﹤0.01% |
75,512
-256,010
| -77% | -$66.9M |
|
|
RERE
1147
ATRenew
RERE
$853M
| $19.8M | ﹤0.01% |
5,121,851
+937,897
| +22% | +$4.16M |
|
|
RNA
1148
Atrium Therapeutics
RNA
$144M
| $19.8M | ﹤0.01% |
1,472,984
-80,226
| -5% | -$1.05M |
|
1149
Gen Digital
GEN
$12.5B
| $19.8M | ﹤0.01% |
795,486
-766,384
| -49% | -$17.1M |
|
1150
Sensient Technologies
SXT
$5.49B
| $19.8M | ﹤0.01% |
160,319
+25,135
| +19% | +$2.8M |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.